Summary. Background: Polyphosphate (a linear polymer of inorganic phosphate) is secreted from platelet dense granules, and we recently showed that it accelerates factor V activation by thrombin. Objective: To examine the interaction of polyphosphate with thrombin. Methods and Results: Thrombin, but not prothrombin, altered the electrophoretic migration of polyphosphate in gel mobility assays. Thrombin binding to polyphosphate was influenced by ionic strength, and was evident even in plasma. Two positively charged exosites on thrombin mediate its interactions with other proteins and accessory molecules: exosite I (mainly with thrombin substrates), and exosite II (mainly with certain anionic polymers). Free thrombin, thrombin in complex with hirudinÕs C-terminal dodecapeptide and c-thrombin all bound polyphosphate similarly, excluding exosite I involvement. Mutations within exosite II, but not within exosite I, the Na + -binding site or hydrophobic pocket, weakened thrombin binding to polyphosphate as revealed by NaCl dependence. Surface plasmon resonance demonstrated tight interaction of polyphosphate with thrombin (K d approximately 5 nM) but reduced interaction with a thrombin exosite II mutant. Certain glycosaminoglycans, including heparin, only partially competed with polyphosphate for binding to thrombin, and polyphosphate did not reduce heparin-catalyzed inactivation of thrombin by antithrombin. Conclusion: Polyphosphate interacts with thrombinÕs exosite II at a site that partially overlaps with, but is not identical to, the heparin-binding site. Polyphosphate interactions with thrombin may be physiologically relevant, as the polyphosphate concentrations achievable following platelet activation are far above the approximately 5 nM K d for the polyphosphate-thrombin interaction.
Introduction
Thrombin interacts with many substrates, modulatory proteins and accessory molecules. As a procoagulant, thrombin converts fibrinogen into fibrin, activates platelets via proteaseactivated receptor (PAR)-1 and PAR-4, and proteolyses clotting factors FV, FVII, FVIII, FXI and FXIII. Thrombin activity is tightly regulated by a number of mechanisms, including binding to thrombomodulin (switching it to an anticoagulant protease), and direct inhibition by plasma protease inhibitors such as antithrombin and heparin cofactor II. ThrombinÕs exquisite specificity is largely determined by its anion-binding exosites I and II, both of which lie distal to the active site. Exosite I interacts with protein substrates and modulators such as fibrinogen [1] , PAR-1 [2] , thrombomodulin [3] and the C-terminal dodecapeptide tail of hirudin [4] , and exosite II interacts with platelet glycoprotein (GP)Iba [5] , protease nexin I [6] , prothrombin activation fragment 2 [7] , heparin [8, 9] and the chondroitin sulfate moiety of thrombomodulin [10] .
Inorganic polyphosphate (polyP), a linear polymer of orthophosphate residues linked via phosphoanhydride bonds, plays important and diverse roles in nature. Dense granules of human platelets contain polyP, which is secreted upon platelet activation [11] . We recently showed that polyP is a potent modulator of blood clotting, and in particular that it enhances thrombin generation by accelerating conversion of FV to FVa [12] . These results led to the hypothesis that polyP interacts directly with thrombin. In this study, we demonstrate that polyP associates with thrombinÕs exosite II by way of tight electrostatic interactions.
Materials and methods

Materials
Materials were from the following suppliers: polyP (sold under the name Ôsodium phosphate glassÕ) of mean polymer lengths 25 (polyP 25 ) and 75+ (polyP 75 ), toluidine blue O, unfractionated heparin (from porcine intestinal mucosa, 140 USP mg
; average chain length 17-19 kDa), heparan sulfate (from bovine kidney), chondroitin sulfate A (from bovine tracheae), chondroitin sulfate B (from porcine intestine) chondroitin sulfate C (from shark cartilage), hyaluronic acid and heparin-agarose beads were from Sigma (St Louis, MO, USA); dextran sulfate (average M r 500 000) was from Fisher Scientific (Pittsburgh, PA, USA); human prothrombin and a-thrombin were from Enzyme Research Laboratories (South Bend, IN, USA); biotin-D-Phe-Pro-Arg chloromethylketone, antithrombin and c-thrombin were from Haematologic Technologies (Essex Junction, VT, USA); polyclonal anti-prothrombin antibody was from Affinity Biologicals (Ancaster, ON, Canada); pooled normal human plasma was from George King Bio-Medical (Overland Park, KS, USA); Spectrozyme TH was from American Diagnostica (Stamford, CT, USA); zirconia beads were from ZirChrom Separations (Anoka, MN, USA); Microcon YM10 concentrators were from Millipore (Billerica, MA, USA); polyacrylamide Ready Gels were from Bio-Rad (Hercules, CA, USA); Handee mini-spin columns, poly(vinylidene fluoride) membranes, avidin-horseradish peroxidase and Gelcode Blue stain were from Pierce (Rockford, IL, USA); the ECL plus detection system was from Amersham Biosciences (Pittsburgh, PA, USA); streptavidin sensor chips were from BIAcore (Piscataway, NJ, USA); and phospholipids were from Avanti Polar Lipids (Alabaster, AL, USA). Vesicles composed of 80% phosphatidylcholine/20% phosphatidylserine were prepared by sonication. Alanine-substituted mutants of thrombin, numbered from the N-terminus of the B-chain (with chymotrypsinogen numbering in braces in some cases), were expressed and purified as previously described [13, 14] . Unless otherwise indicated, polyP concentrations are given throughout this article in terms of the concentration of phosphate monomer (monomer formula: NaPO 3 ).
Gel mobility shift assays
The polyP interaction with thrombin was investigated using native gel electrophoresis. Thrombin (10 lg) was preincubated with polyP 25 (100 lg) for 10 min at ambient temperature before addition of sample buffer (60 mM Tris-HCl, pH 6.8, 10% glycerol, 0.01% bromophenol blue) and resolution on 10% polyacrylamide gels. Gels were stained for protein with Gelcode Blue, or for polyP with 0.25% toluidine blue O in 25% methanol/5% glycerol for 10 min, and destained in the same solution without dye.
Thrombin binding to immobilized polyP
PolyP was immobilized onto porous zirconia beads essentially as previously described [15] . Briefly, 250 mg of zirconia beads was incubated with 10 mg mL )1 polyP 75 in water for 20 h at 37°C, washed with distilled water, blocked with 10% bovine serum albumin (BSA) for 15 h at ambient temperature, and then dried in vacuum at 80°C for 2 h. Control beads were treated with water and BSA only. To conduct binding assays, polyP-zirconia beads (10 mg dry weight) were washed twice with binding buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, ) before addition of the mixture to polyPzirconia beads and analysis of thrombin binding as above.
Binding of 143 pmol of prothrombin to immobilized polyP was analyzed in a similar manner, except that prothrombin was detected by western blots probed with peroxidase-conjugated anti-prothrombin antibody.
Binding of thrombin to heparin-agarose beads Thrombin (27 pmol) was incubated for 30 min at ambient temperature in binding buffer containing 55 lg mL )1 heparin (3 lM, assuming an average chain length of 18 kDa) or 133 lM polyP 75 (equivalent to approximately 1.8 lM polymer), and then incubated with 215 lg of heparin-agarose beads for 30 min, after which thrombin was eluted and detected as described for polyP-zirconia beads.
Binding of thrombin to polyP-zirconia in plasma Thrombin (50 lM) was biotinylated at its active site by reacting it at ambient temperature for 30 min with 500 lM biotin-DPhe-Pro-Arg chloromethylketone, after which it had undetectable enzymatic activity by Spectrozyme TH hydrolysis. Unreacted inhibitor was removed by repeated centrifugation using Microcon YM10 filters. PolyP-zirconia beads were preincubated with plasma or 20 mM Hepes-NaOH (pH 7.4), 150 mM NaCl and 50 mg mL )1 BSA, after which 27 pmol of biotin-thrombin was added to the plasma or BSA-containing buffer. Thrombin-binding assays were performed as described above, with biotin-thrombin being detected by probing western blots with avidin-peroxidase.
Thrombin inhibition by antithrombin
Heparin-catalyzed thrombin inhibition by antithrombin was carried out at the following reactant conditions: 25 nM thrombin, 50 nM antithrombin, 16 mM Hepes-NaOH (pH 7.4), 120 mM NaCl, 0.08% BSA and 0-1000 U mL , or 4 nM). In some experiments, the heparin and polyP 75 concentrations were constant (0.01 U mL )1 or 4 nM and 37.5 lM, respectively) and the salt concentration of the buffer was varied from 50 to 500 mM. Reactions proceeded for 10 min at 37°C before the remaining thrombin activity was quantified (using Spectrozyme TH hydrolysis).
Surface plasmon resonance
Biotin-thrombin, prepared as described above using activesite-specific labeling, was bound to streptavidin sensor chips (in a BIAcore 3000 instrument) until a response of 2000 resonance units (RU) was achieved. Various concentrations of polyP 25 or polyP 75 in 20 mM Hepes-NaOH (pH 7.4), 0.005% P-20, at either 50 mM or 150 mM NaCl, were passed over the chip at 10 lL min )1 until a steady state was reached. Maximal (steady-state) RU values were plotted vs. polyP concentration, to which the single-site ligand-binding equation was fitted.
Regeneration of the thrombin-chip surface was achieved by passing 50 mM Hepes-NaOH (pH 7.4), 1 M NaCl and 0.005% P-20 over it until the response returned to baseline.
Results
We previously showed that polyP accelerates thrombin-catalyzed conversion of FV to FVa [12] . This exhibited a bellshaped concentration dependence, with an optimal polyP 75 concentration of 75 lM (expressed in terms of phosphate monomer; data not shown), consistent with a template mechanism in which both FV and thrombin probably bind to polyP. In this study, we therefore examined how polyP interacts with thrombin.
PolyP binds to thrombin but not prothrombin
We used gel mobility-shift assays in native gels to investigate binding of polyP to prothrombin or thrombin. Toluidine blue staining revealed a pronounced retardation of polyP 25 ( Fig. 1A ) and polyP 75 (not shown) migration in the presence of thrombin but not prothrombin. We further examined thrombin-polyP interactions using polyP 75 immobilized on zirconia beads. When incubated with polyP-zirconia in 50 mM NaCl, thrombin was undetectable in the flow-though (by western blots; Fig. 1B , lane 2) but appeared in the 1 M NaCl eluate (Fig. 1B, lane 3) . PolyP therefore binds to thrombin with an ionic component to the interaction. In contrast, prothrombin appeared in the flow-through but not the 1 M NaCl eluate, indicating a lack of polyP 75 binding (Fig. 1B) . In quantitative experiments (n = 6), thrombin failed to bind to BSA-zirconia beads (25.84 ± 1.3 pmol of thrombin in the flow-through, as compared with 27 pmol of thrombin initially added to the beads) but bound well to polyP-zirconia beads (0.02 ± 0.01 pmol of thrombin in the flow-through). High-salt washes eluted a negligible amount of thrombin from BSAzirconia beads (0.06 ± 0.01 pmol of thrombin), but eluted thrombin essentially quantitatively from the polyP-zirconia beads (23.08 ± 1.14 pmol of thrombin).
Plasma has a very high protein concentration, including proteins that might compete with thrombin for binding to polyP. We therefore evaluated thrombin binding to polyP in plasma. Biotin-thrombin mixed with plasma or a buffer containing 50 mg mL )1 BSA was incubated with polyPzirconia or BSA-zirconia beads. After washing and elution with high-salt buffer, biotin-thrombin was recovered equally well from plasma and buffer (Fig. 1C) , demonstrating that the thrombin-polyP interaction occurs efficiently in a plasma milieu.
We investigated the salt dependence of polyP-thrombin interactions by incubating thrombin with immobilized polyP at increasing NaCl concentrations, yielding half-maximal thrombin-polyP binding at approximately 700 mM NaCl (Fig. 2,  open symbols) . Similarly, thrombin bound to polyP 75 at 50 mM NaCl showed half-maximal elution at approximately 700 mM NaCl (Fig. 2, closed symbols) . PolyP interacts with divalent metal ions, but we found that including 2.5 mM CalCl 2 had no discernible effect on binding of thrombin to, or elution from, immobilized polyP 75 (not shown). Plasma Ca 2+ therefore does not interfere with thrombin-polyP interactions.
Location of the polyP-binding site on thrombin
PolyP is highly anionic, so we investigated the possibility that it interacts with one or both of the anion-binding exosites on thrombin. Binding of thrombin but not prothrombin to polyP indicates that the binding site is masked in the zymogen. Proexosite I in prothrombin is only partially exposed, exhibiting approximately 100-fold decreased affinity for ligands compared to a-thrombin [16, 17] . Exosite II is completely buried within prothrombin, being fully exposed only upon activation to a-thrombin [10, 17, 18] . We observed comparable binding of both a-thrombin and c-thrombin to immobilized polyP 75 , including nearly identical salt sensitivities (Fig. 3A) . Similarly, preincubating thrombin with the C-terminal dodecapeptide of hirudin (a high-affinity exosite I ligand) had no discernible effect on thrombin binding to immobilized polyP 75 (Fig. 3B) . These data exclude a role for exosite I in polyP binding.
Thrombin mutants with alanine substitutions in key regions were employed to investigate the polyP-binding site on thrombin. Wild-type (WT) and mutant thrombins were incubated with immobilized polyP 75 and eluted with increasing NaCl concentrations. Thrombins with point mutations in the Na + -binding site (E229A), the 50-insertion loop that defines the active site hydrophobic pocket (W50A) or exosite I (Y71A; H66A) eluted at essentially the same NaCl concentration (W50A; H66A) or a slightly higher NaCl concentration (E229A; Y71A) than WT thrombin (Fig. 4A) . In contrast, four mutants with substitutions in exosite II (R89A/R93A/ E94A; R98A; K248A; K252A/D255A/Q256A) eluted from immobilized polyP 75 at lower NaCl concentrations than WT thrombin, with the K248A and K252A/D255A/Q256A mutants showing the greatest shift in salt sensitivity (Fig. 4B) . At 500 mM NaCl, a significant reduction in binding was observed with all four mutants (P < 0.05 in all cases) as compared with WT thrombin (Fig. 4C) , with the weakest binding being observed with the K248A mutant (69% ± 3% unbound; P < 0.005) and the exosite II triple mutant K252A/ D255A/Q256A (84% ± 2% unbound; P < 0.0005), as compared with WT thrombin (18% ± 3% unbound).
ThrombinÕs exosite II binds certain glycosaminoglycans, and was originally known as the heparin-binding site [19] . We therefore investigated whether glycosaminoglycans competed with polyP for binding to thrombin. We preincubated thrombin with glycosaminoglycans before adding immobilized polyP 75 , after which the flow-through was analyzed for thrombin activity (Fig. 5A ). Dextran sulfate, heparin and heparan sulfate partially competed with polyP 75 for binding to thrombin, with approximately half of the thrombin remaining unbound. On the other hand, chondroitin sulfate A, B and C were relatively weak competitors, and hyaluronic acid showed negligible competition. In another experiment, thrombin was preincubated with heparin or polyP 75 , and then added to heparin-agarose beads (Fig. 5B) . In the absence of competitor, all of the thrombin bound to heparin-agarose and was recovered by elution with 1 M NaCl. As expected, heparin abrogated thrombin binding to heparin-agarose. In contrast, polyP 75 only partially diminished thrombin binding to heparin-agarose, with 29% of the thrombin remaining in the flowthrough and 48% being recovered in the high-salt eluate.
Functional analyses of heparin-catalyzed antithrombin inhibition of thrombin revealed little or no interference by polyP 75 over a range of heparin concentrations (Fig. 6A) , indicating that polyP does not affect either aspect of the template mechanism. Similarly, a range of polyP 75 concentrations failed to interfere with heparin-catalyzed antithrombin Inorganic polyphosphate (polyP) interaction with thrombin is influenced by salt concentration. Thrombin was incubated with polyPzirconia beads at varying NaCl concentrations, after which the activity of unbound thrombin was quantified in the flow-through (s). Alternatively, thrombin was incubated with polyP-zirconia beads in binding buffer containing 50 mM NaCl, and the activity of bound thrombin was quantified after elution with increasing NaCl concentrations (d). Data represent mean ± standard deviation (n = 3). ), after which the mixtures were incubated with polyP-zirconia beads in binding buffer containing 50 mM or 1 M NaCl. Thrombin activity was quantified in the flow-through. Data represent mean ± standard deviation (n = 3).
inhibition of thrombin (Fig 6B) . Experiments performed over a range of salt concentrations (50-500 mM NaCl) did not reveal any additional interference of polyP 75 in the heparin-catalyzed antithrombin inhibition of thrombin (data not shown). These findings are consistent with the experiments above showing that polyP does not block heparin binding to thrombin. WT thombin and the K248A (236) exosite II mutant of thrombin were biotinylated at their active sites and immobilized onto streptavidin sensor chips for surface plasmon resonance studies. Increasing polyP concentrations were passed over the surface of the chip until steady-state binding was achieved (Fig. 7) . From these data, binding constants for polyP association with thrombin were derived. In the presence of 50 or 150 mM NaCl, ): DS, dextran sulfate; H, heparin; HS, heparan sulfate; CA, chondroitin sulfate A; CB, chondroitin sulfate B; CC, chondroitin sulfate C; HA, hyaluronic acid. Mixtures were incubated with polyP-zirconia beads or zirconia beads only (labeled ÔNo polyPÕ), after which unbound thrombin in the flow-through was quantified. (B) Thrombin (27 pmol) was preincubated with buffer alone, or with 55 lg mL )1 heparin (equivalent to 3 lM) or 130 lM polyP 75 (equivalent to 1.8 lM polymer). The mixtures were then incubated with heparin-agarose beads (50 lL), and thrombin activity in the flow-through (open bars) and high-salt eluate (closed bars) was quantified.
polyP 75 bound with very high affinity to WT thrombin (Table 1) , and similar binding isotherms were obtained with polyP 25 (not shown). Binding of polyP 75 to the K248A (236) exosite II mutant of thrombin was reduced at 50 mM NaCl as compared with WT thrombin, resulting in an approximately 2.5-fold higher K d value (P < 0.005). Interestingly, binding of polyP 75 to the K248A mutant was undetectable at 150 mM NaCl, supporting the observations that polyP interactions with thrombin are highly dependent on the NaCl concentration.
Discussion
We previously showed that polyP accelerates FV activation by thrombin [12] . PolyP is highly anionic, leading us to hypothesize that it binds to one of thrombinÕs anion-binding exosites.
We found clear evidence that polyP interacts with high affinity with exosite II, which is the more basic of thrombinÕs two exosites and is known to bind a number of anionic glycosaminoglycans [19] . Interaction of polyP with exosite I was ruled out, as polyP bound equally well to thrombin in complex with the C-terminus of hirudin [4] and to c-thrombin, a proteolytic derivative in which exosite I is impaired [20] . Experiments using thrombins mutated in exosites I and II, and also using competitors that bind to these regions, showed that polyP binding to thrombin requires exosite II. The interaction clearly has an ionic component, as high NaCl concentrations weakened thrombin binding to polyP. Another similarity between polyP and known exosite II ligands lies in the cofactor role that polyP plays in the positive feedback of thrombin-catalyzed FV activation. Both exosites on thrombin have been implicated in FV activation [21, 22] , and we propose that polyP binding to exosite II promotes bridging of thrombin to FV, thereby facilitating cleavage and FVa formation. This ÔapproximationÕ phenomenon is well documented in terms of thrombinÕs activation of FXI via linkage with GPIb [23] , of FXIII via linkage with fibrin [24] and of both protein C [25, 26] and thrombin-activatable fibrinolysis inhibitor [14] through interaction with thrombomodulin. This is in addition to the clearly characterized roles of glycosaminoglycan cofactors during thrombin inhibition by antithrombin and heparin cofactor II. The role of cofactors in the regulation of thrombin activity extends the enzymeÕs substrate specificity and appears to be crucial to its lifespan in the body [27] . To date, no cofactor has been reported to be involved in the early reactions elicited by thrombin, that is, cleavage of fibrinogen to fibrin, or activation of FV or FVIII [27] . Our data suggest that polyP may function in regulating thrombin activity at this time. During primary hemostasis, circulating platelets will contact the damaged endothelium, becoming activated; this will result in release of polyP and exposure of negatively charged phospholipids, required for assembly of the prothrombinase complex. During these initial stages of coagulation, polyP is in a prime position to bind newly generated thrombin and enhance back-activation of FV to stimulate further thrombin formation. Further studies will be necessary to define how thrombin transitions through its different cofactors during its lifespan; this is most probably influenced by the availability, location and binding affinities of the reactants. Binding of heparin to thrombin has been localized through mutagenesis studies [19, [28] [29] [30] and confirmed by high-resolution crystallography [31] . The interaction is ionic in nature and involves residues Arg89 {93}, Lys248 {236}, Lys252 {240}, Arg98 {101} and Arg245 {233} (in decreasing order of contribution to heparin binding) [31] . The data presented here indicate that, although some overlap exists in the binding sites for heparin and polyP within exosite II, they are not identical. Interaction of both heparin and polyP with thrombin depends on some common residues such as Lys248 {236} and Lys252 {240}, but, importantly, mutating Arg89 {93} -which is most crucial for heparinÕs interaction with thrombin -had the least impact on polyP interaction with thrombin. A similar situation is observed with heparin and prothrombin fragment 2, with a degree of overlap in the binding sites of these molecules on thrombin but with only one common residue in exosite II involved [32] . He et al. [33] showed that interactions occurring at exosite II in thrombin are mediated by different arginines. The unique specificity of residues in this region and the weak influence of Arg89 {93} and Arg98 {101} on polyP binding to thrombin help to explain the lack of competition with heparin. We observed only partial competition between heparin and polyP for binding to exosite II, and, furthermore, polyP did not appreciably interfere with heparin-catalyzed thrombin inhibition by antithrombin. This suggests that both ligands can bind to the same thrombin molecule. In the crystal structure of heparin bound to exosite II of thrombin (Fig. 8) , Arg89 {93} and Arg98 {101} (which were the least important in polyP binding but the most important in heparin binding) lie on one side of the bound heparin molecule, and Lys248 {236} and Lys252 {240} (which are very important for polyP binding) lie on the opposite side of the bound heparin. Furthermore, these latter residues appear to be more solventaccessible, even in the presence of bound heparin. Further mutagenesis and crystallographic studies are required to resolve the extent of the overlap in polyP and heparin binding. Competition between polyP and chrondroitin sulfate was even less apparent than that between polyP and heparin, despite its known binding to exosite II [10] . The residues important in this interaction are assumed to be similar to those important for heparin binding, but have not been extensively defined. It is possible that the chondrotin sulfate-thrombin interaction has a lower affinity than the heparin-thrombin interaction, which would explain the reduced competition with polyP.
The concentration of polyP 75 in whole blood may reach 3 lM following platelet activation, and much higher levels are expected in platelet-rich thrombi [11, 12] . This polyP concentration is far above the 5 nM K d of the polyP-thrombin interaction, suggesting that complex formation is favored in vivo. PolyP may therefore act as a physiologic modulator of thrombin function. Fig. 8 . Thrombin-heparin cocrystal structure. Thrombin is rendered as space-filling, with Lys and Arg side chains in blue, and heparin is rendered as red wires. Key Lys and Arg residues implicated in heparin and/or polyP binding are indicated by arrows, using thrombin numbering, with chymotrypsinogen equivalents in braces. The Structure is from PDB file 1XMN [31] .
